Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
1don MSN
The valuation backdrop for small-caps and mid-caps continue to look compelling for investors looking to add exposure, said ...
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Merck (NYSE:MRK) announced Thursday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent ...
Zacks.com on MSN1d
Exelixis Gets Favorable Ruling in Patent Litigation With MSNExelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation ...
Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL – Research Report). The ...
Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Exelixis (EXEL – Research Report). The associated price ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback